文献速递水电解质与酸碱慢性肾脏病

日本持续医疗背景下真实世界患者高钾血症研究

Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan.
PubMed 文献 · Kidney Int Rep · 2019-05-30

基于日本医院理赔数据库(2008年4月至2017年9月,N=1,022,087)的回顾性观察队列研究,评估血清钾水平与3年生存的关系及高钾血症管理。高钾血症患病率为每1000人67.9例,在CKD、心衰和RAASi使用患者中更高;血清钾与3年生存呈U型关联,最低点在4.0 mEq/L,5.1-5.4 mEq/L时死亡风险比为7.6。尽管使用袢利尿剂和钾结合剂,超过30%患者血钾持续≥5.1 mEq/L。

要点

  • 高钾血症在CKD、心衰和RAASi使用患者中患病率更高。
  • 血清钾与3年生存呈U型关联,最低点在4.0 mEq/L。
  • 血清钾5.1-5.4 mEq/L时死亡风险比为7.6。

核心结论

  • 高钾血症在真实世界患者中常见,且与3年生存呈U型关联,低钾和高钾均增加死亡风险。

研究设计与样本

  • 采用日本医院理赔数据库的观察性回顾性队列研究,纳入2008年4月至2017年9月共1,022,087例患者。

主要发现

  • 高钾血症患病率为每1000人67.9例(95%CI:67.1-68.8)。
  • CKD患者高钾血症患病率为每1000人227.9例(95%CI:224.3-231.5),心衰患者为134.0例(95%CI:131.2-136.8),RAASi使用者为142.2例(95%CI:139.6-144.7)。
  • 血清钾与3年生存呈U型关联,最低点在4.0 mEq/L;血清钾5.1-5.4 mEq/L时死亡风险比为7.6(95%CI:7.2-8.0)。
  • CKD 3a、3b、4、5期血钾正常患者3年死亡率分别为1.51%、3.93%、10.86%、12.09%;CKD 3a期患者血清钾5.1-5.4、5.5-5.9、≥6.0 mEq/L时3年死亡率分别升至10.31%、11.43%、22.64%。
  • 尽管使用袢利尿剂(18.5%)和钾结合剂(5.8%),超过30%患者血清钾持续≥5.1 mEq/L。

临床怎么用

  • 在CKD、心衰和RAASi使用患者中应加强血钾监测与管理。
  • 血清钾5.1-5.4 mEq/L即与死亡风险显著增加相关,需引起临床重视。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: An abnormal serum potassium (S-K) level is an important electrolyte disturbance. However, its relation to clinical outcomes in real-world patients, particularly hyperkalemia burden, is not extensively studied. METHODS: An observational retrospective cohort study using a Japanese hospital claims database was done (April 2008-September 2017; N = 1,022,087). Associations between index S-K level and 3-year survival were modeled using cubic spline regression. Cox regression model was applied to estimate the time to death according to different S-K levels. Prevalence, patient characteristics, treatment patterns, and management of patients with hyperkalemia from first episode were assessed. RESULTS: Hyperkalemia prevalence was 67.9 (95% confidence interval [CI]: 67.1-68.8) per 1000 and increased in patients with chronic kidney disease (CKD) (227.9; 95% CI: 224.3-231.5), heart failure (134.0; 95% CI: 131.2-136.8), and renin-angiotensin-aldosterone system inhibitor (RAASi) use (142.2; 95% CI: 139.6-144.7). U-shaped associations between S-K level and 3-year survival were observed with nadir 4.0 mEq/l. The risk of death was increased at S-K 5.1-5.4 mEq with hazard ratio of 7.6 (95% CI: 7.2-8.0). The 3-year mortality rate in patients with CKD stages 3a, 3b, 4, and 5 with normokalemia were 1.51%, 3.93%, 10.86%, and 12.09%, whereas that in patients with CKD stage 3a at S-K 5.1-5.4, 5.5-5.9, and ≥6.0 mEq/l increased to 10.31%, 11.43%, and 22.64%, respectively. Despite treatment with loop diuretics (18.5%) and potassium binders (5.8%), >30% of patients had persistently high S-K (≥5.1 mEq/l). CONCLUSION: This study provides real-world insight on hyperkalemia based on a large number of patients with various medical backgrounds.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kashihara N, Kohsaka S, Kanda E, et al. Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan. Kidney Int Rep. 2019. PMID: 31517144. doi:10.1016/j.ekir.2019.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。